ENDRA Life Sciences Reports Q1 2025 Financial Results with Reduced Net Loss

ENDRA Life Sciences Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $1,036,330, a significant reduction from the net loss of $2,775,700 recorded in the same period of the previous year. The company did not generate any revenue during this quarter, consistent with its performance in the first quarter of 2024. Operating expenses decreased to $1,469,282, down 47% from $2,780,541 in the prior year, primarily due to reduced spending in research and development, sales and marketing, and general and administrative costs.

Research and development expenses were $528,685 for the three months ended March 31, 2025, compared to $1,041,526 in the same period last year, marking a 49% decrease. This reduction reflects the company's shift in focus from product development to clinical trials and commercialization efforts for its TAEUS technology. Sales and marketing expenses also saw a significant decline, falling 71% to $68,991, attributed to a restructuring of sales operations initiated in 2024. General and administrative expenses decreased by 42% to $871,606, driven by lower wage-related expenses and professional fees.

ENDRA's total assets decreased to $3,170,598 as of March 31, 2025, down from $4,452,362 at the end of 2024. The decline in assets was accompanied by a reduction in total liabilities, which fell to $1,417,713 from $1,891,996. The company's cash position also weakened, with cash and cash equivalents at $2,064,874, down from $3,229,480 at the end of the previous fiscal year. The accumulated deficit increased to $104,474,429, reflecting the ongoing financial challenges faced by the company.

In terms of strategic developments, ENDRA has not yet commercialized its TAEUS technology, which focuses on non-invasive tissue characterization. The company is exploring a subscription-based business model to enhance market penetration and is leveraging artificial intelligence to improve the accuracy of its technology. However, the company has indicated that it will require additional financing to support its operations and product development, as it has not established a consistent revenue stream. Management is considering various financing options, including equity sales and potential collaborations, to secure the necessary capital.

Looking ahead, ENDRA acknowledges the uncertainty surrounding its ability to continue as a going concern without additional funding. The company plans to continue its focus on advancing the TAEUS technology and pursuing regulatory approvals, but it faces significant risks and challenges in achieving these objectives. The financial statements for the quarter ended March 31, 2025, have been prepared under the assumption that the company will continue as a going concern, but the ability to do so is contingent on securing adequate capital to fund ongoing operations.